June 16, 2015 Link here – Adherium (NZ) Limited (formerly Nexus6) has received ISO 13485 medical device quality management system certification for operations at its New Zealand head office. ISO 13485 is an international quality management standard that covers all aspects of a medical device company’s operations from product development to manufacturing to customer support. It has […]
Placing and Subscription to raise £2.1 million and proposed Additional Fundraising to raise approximately £1.0 million and Share Restructuring. Link here. 12 June 2015 Rex Bionics Plc (AIM: RBX), the pioneer of the REX Robot technology that enhances the mobility of wheelchair users, today announces a proposed Placing and Subscription of 3,500,000 New Ordinary Shares at […]
/wp-content/uploads/2018/01/BSM_logo.png00keymaster/wp-content/uploads/2018/01/BSM_logo.pngkeymaster2015-06-12 17:37:362018-01-06 17:38:11Rex Bionics plc – Proposed Fundraising and Notice of General Meeting
Results presented at the 38th European Cystic Fibrosis Conference Link here. San Diego and Richmond, VA, USA, Ljubljana, Slovenia, and Sydney, Australia, June 12, 2015 – AmpliPhi BioSciences Corporation (OTCQB: APHB), a global leader in the development of bacteriophage-based antibacterial therapies to treat drug resistant infections, today announced new data demonstrating that bacteriophages remain active against Pseudomonas aeruginosa (P. […]
/wp-content/uploads/2018/01/BSM_logo.png00keymaster/wp-content/uploads/2018/01/BSM_logo.pngkeymaster2015-06-12 17:36:512018-01-06 17:37:26AmpliPhi Announces New Data Demonstrating Anti-Pseudomonal Bacteriophages Retained Biological Activity Following Nebulization
FINANCIAL RESULTS FOR THE 12 MONTHS TO 31 MARCH 2015. Link here. SeaDragon annual sales double; Omega 3 refinery on track for start-up in Q4 2015 Highlights: • New Omega 3 fish oil refinery on track for commissioning later this year, realising a 10 year strategic plan • Additional Squalene raw material supply contracts position SeaDragon for […]
/wp-content/uploads/2018/01/BSM_logo.png00keymaster/wp-content/uploads/2018/01/BSM_logo.pngkeymaster2015-06-10 17:42:172018-01-06 17:42:59SeaDragon Full Year Result to 31 March 2015
Results to be presented at the 38th European Cystic Fibrosis Conference. Link here. San Diego and Richmond, VA, USA, Ljubljana, Slovenia, and Sydney, Australia, June 8, 2015 – AmpliPhi BioSciences Corporation (OTCQB: APHB), a global leader in the development of bacteriophage-based antibacterial therapies to treat drug resistant infections, today announced that new data on the activity of […]
/wp-content/uploads/2018/01/BSM_logo.png00keymaster/wp-content/uploads/2018/01/BSM_logo.pngkeymaster2015-06-08 17:39:002018-01-06 17:39:29AmpliPhi to Present New Data on Biological Activity of Nebulized Anti-Pseudomonal Bacteriophage
Nexvet Advances Manufacturing Strategy. Link here. Agreement signed with FUJIFILM Diosynth Biotechnologies Key appointment made in Ireland DUBLIN, Ireland and MELBOURNE, Australia, June 8, 2015 (GLOBE NEWSWIRE) — Nexvet Biopharma (Nasdaq:NVET), a veterinary biologics developer, announced today an update to its manufacturing strategy. Nexvet has signed a manufacturing agreement with FUJIFILM Diosynth Biotechnologies (Fujifilm) to provide […]
DUBLIN, Ireland and MELBOURNE, Australia, June 4, 2015 (GLOBE NEWSWIRE) Link here. Nexvet Biopharma (Nasdaq:NVET), a veterinary biologics developer, today announced statistically significant top-line results from its proof-of-concept (POC) efficacy study of NV-02, an anti-nerve growth factor (NGF) monoclonal antibody (mAb) therapy in development for the control of pain associated with degenerative joint disease (DJD), including […]
/wp-content/uploads/2018/01/BSM_logo.png00keymaster/wp-content/uploads/2018/01/BSM_logo.pngkeymaster2015-06-04 17:39:392018-01-06 17:40:15Nexvet Announces Positive Top-Line Results for Proof-of-Concept Efficacy Study of NV-02 in Cats With Degenerative Joint Disease
First cGMP-certified manufacturing facility commissioned to manufacture bacteriophage products for human use. Link here. San Diego and Richmond, VA, USA, Ljubljana, Slovenia, and Sydney, Australia, June 3, 2014 – AmpliPhi BioSciences Corporation. (OTCQB: APHB), a global leader in developing bacteriophage-based antibacterial therapies to treat drug resistant infections, announced today that its production facility in Ljubljana, Slovenia, was […]
1 June 2015 Rex Bionics Plc (AIM: RBX), the pioneer of the REX Robot technology that enhances the mobility of wheelchair users, is pleased to announce that the first patient has been successfully treated in its RAPPER II (“Robot-Assisted PhysiotheraPy Exercises with REX”) clinical trial. Link here. A 37 year-old male with a spinal cord injury at level T3, […]
/wp-content/uploads/2018/01/BSM_logo.png00keymaster/wp-content/uploads/2018/01/BSM_logo.pngkeymaster2015-06-01 17:41:332018-01-06 17:42:06Rex Bionics – First Patient Treated in RAPPER II Clinical Trial
29 May 2015, Rex Bionics Plc (AIM: RXB) the pioneer of the REX Robot technology that enhances the mobility of wheel-chair users and enables robot assisted physiotherapy exercise, today announces its audited results for the sixteen month period ending 31 March 2015. Link here.
Adherium Receives ISO 13485 Certification
/in Adherium, Portfolio CompaniesJune 16, 2015 Link here – Adherium (NZ) Limited (formerly Nexus6) has received ISO 13485 medical device quality management system certification for operations at its New Zealand head office. ISO 13485 is an international quality management standard that covers all aspects of a medical device company’s operations from product development to manufacturing to customer support. It has […]
Rex Bionics plc – Proposed Fundraising and Notice of General Meeting
/in Portfolio Companies, Rex BionicsPlacing and Subscription to raise £2.1 million and proposed Additional Fundraising to raise approximately £1.0 million and Share Restructuring. Link here. 12 June 2015 Rex Bionics Plc (AIM: RBX), the pioneer of the REX Robot technology that enhances the mobility of wheelchair users, today announces a proposed Placing and Subscription of 3,500,000 New Ordinary Shares at […]
AmpliPhi Announces New Data Demonstrating Anti-Pseudomonal Bacteriophages Retained Biological Activity Following Nebulization
/in Armata Pharmaceuticals, Portfolio CompaniesResults presented at the 38th European Cystic Fibrosis Conference Link here. San Diego and Richmond, VA, USA, Ljubljana, Slovenia, and Sydney, Australia, June 12, 2015 – AmpliPhi BioSciences Corporation (OTCQB: APHB), a global leader in the development of bacteriophage-based antibacterial therapies to treat drug resistant infections, today announced new data demonstrating that bacteriophages remain active against Pseudomonas aeruginosa (P. […]
SeaDragon Full Year Result to 31 March 2015
/in Portfolio Companies, SeaDragonFINANCIAL RESULTS FOR THE 12 MONTHS TO 31 MARCH 2015. Link here. SeaDragon annual sales double; Omega 3 refinery on track for start-up in Q4 2015 Highlights: • New Omega 3 fish oil refinery on track for commissioning later this year, realising a 10 year strategic plan • Additional Squalene raw material supply contracts position SeaDragon for […]
AmpliPhi to Present New Data on Biological Activity of Nebulized Anti-Pseudomonal Bacteriophage
/in Armata Pharmaceuticals, Portfolio CompaniesResults to be presented at the 38th European Cystic Fibrosis Conference. Link here. San Diego and Richmond, VA, USA, Ljubljana, Slovenia, and Sydney, Australia, June 8, 2015 – AmpliPhi BioSciences Corporation (OTCQB: APHB), a global leader in the development of bacteriophage-based antibacterial therapies to treat drug resistant infections, today announced that new data on the activity of […]
Nexvet Advances Manufacturing Strategy
/in Pharmamark, Portfolio CompaniesNexvet Advances Manufacturing Strategy. Link here. Agreement signed with FUJIFILM Diosynth Biotechnologies Key appointment made in Ireland DUBLIN, Ireland and MELBOURNE, Australia, June 8, 2015 (GLOBE NEWSWIRE) — Nexvet Biopharma (Nasdaq:NVET), a veterinary biologics developer, announced today an update to its manufacturing strategy. Nexvet has signed a manufacturing agreement with FUJIFILM Diosynth Biotechnologies (Fujifilm) to provide […]
Nexvet Announces Positive Top-Line Results for Proof-of-Concept Efficacy Study of NV-02 in Cats With Degenerative Joint Disease
/in Pharmamark, Portfolio CompaniesDUBLIN, Ireland and MELBOURNE, Australia, June 4, 2015 (GLOBE NEWSWIRE) Link here. Nexvet Biopharma (Nasdaq:NVET), a veterinary biologics developer, today announced statistically significant top-line results from its proof-of-concept (POC) efficacy study of NV-02, an anti-nerve growth factor (NGF) monoclonal antibody (mAb) therapy in development for the control of pain associated with degenerative joint disease (DJD), including […]
AmpliPhi’s Bacteriophage Manufacturing Facility Receives cGMP Certification
/in Armata Pharmaceuticals, Portfolio CompaniesFirst cGMP-certified manufacturing facility commissioned to manufacture bacteriophage products for human use. Link here. San Diego and Richmond, VA, USA, Ljubljana, Slovenia, and Sydney, Australia, June 3, 2014 – AmpliPhi BioSciences Corporation. (OTCQB: APHB), a global leader in developing bacteriophage-based antibacterial therapies to treat drug resistant infections, announced today that its production facility in Ljubljana, Slovenia, was […]
Rex Bionics – First Patient Treated in RAPPER II Clinical Trial
/in Portfolio Companies, Rex Bionics1 June 2015 Rex Bionics Plc (AIM: RBX), the pioneer of the REX Robot technology that enhances the mobility of wheelchair users, is pleased to announce that the first patient has been successfully treated in its RAPPER II (“Robot-Assisted PhysiotheraPy Exercises with REX”) clinical trial. Link here. A 37 year-old male with a spinal cord injury at level T3, […]
Rex Bionics – Audited Results period ended 31 Mar 2015
/in Portfolio Companies, Rex Bionics29 May 2015, Rex Bionics Plc (AIM: RXB) the pioneer of the REX Robot technology that enhances the mobility of wheel-chair users and enables robot assisted physiotherapy exercise, today announces its audited results for the sixteen month period ending 31 March 2015. Link here.